Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer

Prostate

Volumn 54, Issue 2, 2003, Pages 103-111

  Matsuyama, Hideyasu ^a   Pan, Yi ^b   Yoshihiro, Satoru ^a   Kudren, David ^b   Naito, Katsusuke ^a   Bergerheim, Ulf S R ^b   Ekman, Peter ^b  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Disease progression; Fluorescence in situ hybridization (FISH); Tumor suppressor gene

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CHROMOSOME 10Q; CHROMOSOME 16Q; CHROMOSOME 8P; CHROMOSOME DELETION; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 8; DISEASE PROGRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 0037307128     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10173     Document Type: Article

References (35)

1. Trapasso J, deKernion J, Smith R, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-1825.
2. Partin A, Kattan M, Subong E, Walsh P, Wojno K, Oesterling J, Scardino P, Pearson J. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-1451.
3. Bergerheim USR, Kunimi K, Collins VP, Ekman P. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosom Cancer 1991;3:215-220.
4. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH. Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 1995;153:249-254.
5. Eagle L, Yin X, Brothman A, Williams B, Atkin N, Prochownik E. Mutation of the MX11 gene in prostate cancer. Nat Genet 1995;9:249-255.
6. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman J, Jen J, Isaacs W, Bova G, Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
7. Dong J, Suzuki H, Pin S, Bova G, Schalken J, Isaacs W, Barrett J, Isaacs J. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56:4387-4390.
8. Nasu Y, Timme T, Yang G, Bangma C, Li L, Ren C, Park S, DeLeon M, Wang J, Thompson T. Suppression of caveolin expression induces androgen sensitivity in metastatic androgeninsensitive mouse prostate cancer cells. Nat Med 1998;4:1062-1064.
9. Pan Y, Matsuyama H, Wang N, Yoshihiro S, Haggarth L, Li C, Tribukait B, Ekman P, Bergerheim U. Chromosome 16q24 deletion and decreased E-cadherin expression: Possible association with metastatic potential in prostate cancer. Prostate 1998; 36:31-38.
10. Suzuki H, Freije D, Nusskern D, Okami K, Cairns P, Sidransky D, Isaacs W, Bova G. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-209.
11. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999;91:1574-1580.
12. Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P, Bergerheim US. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 1994;9:3071-3076.
13. Huang S, Xiao S, Renshaw A, Loughlin K, Hudson T, Fletcher J. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. Am J Pathol 1996;149:1565-1573.
14. Alers J, Krijtenburg P, Rosenberg C, Hop W, Verkerk A, Schroder F, van der Kwast T, Bosman F, van Dekken H. Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 1997;77:437-448.
15. Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hagarth L, Kudren D, Naito K, Bergerheim US, Ekman P. Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clin Cancer Res 2001; 7:3139-3143.
16. Schellhammer P, el-Mahdi A, Kuban D, Wright GJ. Prostatespecific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir. Urol Clin North Am 1997;24:407-414.
17. Hermanek P, Sobins LH. UICC. TNM classification of malignant tumours. Geneva: Springer-Verlag; 1978. pp 124-125.
18. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours. Internaational histological classification of tumours. Geneva: World Health Organization; 1980.
19. Matsuyama H, Bergerheim USR, Nilsson I, Pan Y, Skoog L, Tribukait B, Ekman P. Non-random numerical aberrations of chromosomes 7, 9, and 10 in DNA-diploid bladder cancer. Cancer Genet Cytogenet 1994;77:118-124.
20. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 1999;96:3928-3933.
21. Cabeza AY, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 2001;20:4169-4179.
22. Oba K, Matsuyama H, Yoshihiro S, Kishi F, Takahashi M, Tsukamoto M, Kinjo M, Sagiyama K, Naito K. Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer Genet Cytogenet 2001;124:20-26.
23. Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosom Cancer 1998;21:131-143.
24. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate SC, Carter KC. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997; 43:69-77.
25. Washburn JG, Wojno KJ, Dey J, Powell IJ, Macoska JA. 8pter-p23 deletion is associated with racial differences in prostate cancer outcome. Clin Cancer Res 2001;6:4647-4652.
26. Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB. ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci USA 2001; 98:4575-4580.
27. Ford S, Gray IC, Spurr NK. Rearrangement of the long arm of chromosome 10 in the prostate adenocarcinorna cell line LNCaP. Cancer Genet Cytogenet 1998;102:6-11.
28. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosom Cancer 1996;17:225-233.
29. Elo J, Harkonen P, Kyllonen A, Lukkarinen O, Poutanen M, Vihko R, Vihko P. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997;57:3356-3359.
30. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions. Cancer Res 1997;57:1058-1062.
31. Koyama K, Emi M, Nakamura Y. The cell adhesion regulator (CAR) gene, Taq1 and insersion/deletion polymorphisms, and regional assignment to the peritelomeric region of 16q by linkage analysis. Genomics 1993;16:264-265.
32. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-419.
33. Ichikawa D, Hashimoto N, Hoshima M, Yamaguchi T, Sawai K, Nakamura Y, Takahashi T, Abe T, Inazawa J. Analysis of numerical aberrations in specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer 1996;77:2064-2069.
34. Takahashi S, Qian J, Brown J, Alcaraz A, Bostwick D, Lieber M, Jenkins R. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994;54:3574-3579.
35. Macintosh C, Stower M, Reid N, Maitland N. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998;58:23-28.